Search

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...

NICE drugs: an update on what’s good to go

Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...

Reflections on a twelve-year partnership: The Makassar-Dundee LINK

In the first article of a two-part series (see Part 2 here), the authors provide an overview of this hugely successful partnership and how they overcame the challenges of COVID-19. What began in 2008 as a connection between equals, has...

6.6.2020 – a celebration of international partnerships

The date 6.6.2020 was selected as a significant milestone for celebrating the achievements of the VISION LINKS Programme as part of the global ‘VISION 2020: The Right to Sight’ initiative [1]. This virtual full-day seminar included LINK partners in the...

Eyes on the road – visual standards for car drivers

The author examines the current visual standards required by drivers and asks whether more needs to be done to make roads safer. Are the public adequately protected by the current system of visual standards required by drivers? In a survey...

Working smarter not harder: How to transform eyecare delivery in the United Kingdom (part 2)

Are we doing enough to meet the current demands on ophthalmic services? In part two of a two-part series (see Part 1 here), Rosalind Harrison explains how efficiency can be improved by setting up eye services in community hubs. The...

Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service

The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...

Sustainability in eyecare: Climate action in eyecare

Climate change will cause disruption to critical eyecare services and increases in rates of eye disease around the world. The International Agency for Prevention of Blindness has recommended 10 key areas of action on how the eyecare sector can address...

Isolated trochlear (fourth cranial) nerve palsy in an Asian population

The authors report on 35 consecutive new cases of isolated fourth cranial nerve palsy seen over a period of six months in one neuro-ophthalmology clinic in Southeast Asia, with emphasis on their aetiology and management. We report on 35 patients...

The role of injection assistant devices in establishing a nurse-led AMD service

The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...

Sickle cell eye disease: an overview of vitreoretinal complications and their surgical management

Sickle cell disease is the most common genetic disorder worldwide and is associated with lifelong anaemia, intermittent pain and multi-organ morbidity. Ocular involvement can be associated with significant visual impairment due to the complications of proliferative sickle retinopathy (PSR). Occasionally...